[go: up one dir, main page]

HRP20191584T1 - Anti-cd79b protutijela i načini uporabe - Google Patents

Anti-cd79b protutijela i načini uporabe Download PDF

Info

Publication number
HRP20191584T1
HRP20191584T1 HRP20191584T HRP20191584T1 HR P20191584 T1 HRP20191584 T1 HR P20191584T1 HR P20191584 T HRP20191584 T HR P20191584T HR P20191584 T1 HRP20191584 T1 HR P20191584T1
Authority
HR
Croatia
Prior art keywords
seq
hvr
amino acid
acid sequence
cd79b antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Liping L Sun
Yvonne Man-Yee Chen
Mark S Dennis
Allen J Ebens Jr
Andrew Polson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55022708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191584(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20191584T1 publication Critical patent/HRP20191584T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (33)

1. Izolirano anti-CD79b protutijelo, naznačeno time, da protutijelo sadrži domenu vezivanja CD79b koja sadrži sljedećih šest hipervarijabilnih regija (HVR): (a) HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 5; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 8; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 9; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 10; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 11; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 12.
2. Anti-CD79b protutijelo patentnog zahtjeva 1, naznačeno time, da domena vezivanja CD79b sadrži sljedećih šest HVR-regija: (a)HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 3; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 6; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 9; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 10; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 11; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 12. ili, pri čemu domena vezivanja CD79b sadrži sljedećih šest HVR-regija: (a) HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 4; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 7; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 9; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 10; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 11; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 12.
3. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 1 ili 2, naznačeno time, da sadrži VH sekvencu od SEQ ID NO: 17, 21, 23, 25, 27 ili 29.
4. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 3, naznačeno time, da sadrži VL sekvencu od SEQ ID NO: 18, 22, 24, 26, 28 ili 30.
5. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 1 ili 2, naznačeno time, da sadrži VH sekvencu od SEQ ID NO: 19
6. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 2 ili 5, naznačeno time, da sadrži VL sekvencu od SEQ ID NO: 20.
7. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 6, naznačeno time, da domena vezivanja CD79b vezuje humani CD79b s vrijednošću Kd od manje od oko 25 nM kao dvostruko bivalentno IgG protutijelo, manje od oko bilo koje od vrijednosti 10 nM ili 5 nM.
8. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 7, naznačeno time, da je anti-CD79b protutijelo monoklonalno, humanizirano, kimerno protutijelo ili fragment protutijela koji vezuje CD79b.
9. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 8, naznačeno time, da anti-CD79b protutijelo sadrži mutaciju mjesta aglikozilacije.
10. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 9, naznačeno time, da anti-CD79b protutijelo sadrži smanjenu efektorsku funkciju.
11. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 10, naznačeno time, da anti-CD79b protutijelo sadrži zamjensku mutaciju u aminokiselinskom ostatku N297, L234, L235 i/ili D265 prema EU numeriranju.
12. Anti-CD79b protutijelo patentnog zahtjeva 11, naznačeno time, da je zamjenska mutacija odabrana iz skupine koja se sastoji iz N297G, N297A, L234A, L235A i D265A prema EU numeriranju.
13. Anti-CD79b protutijelo patentnog zahtjeva 11, naznačeno time, da protutijelo sadrži zamjensku mutaciju N297G u aminokiselinskom ostatku 297 prema EU numeriranju.
14. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 13, naznačeno time, da je anti-CD79b protutijelo multispecifično ili bispecifično protutijelo.
15. Anti-CD79b protutijelo patentnog zahtjeva 14, naznačeno time, da multispecifično ili bispecifično protutijelo sadrži domenu vezivanja CD3.
16. Anti-CD79b protutijelo patentnog zahtjeva 15, naznačeno time, da domena vezivanja CD3 sadrži sljedećih šest HVR-regija: (a) HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 45; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 46; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 47; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 48; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 49; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 50.
17. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili 16, naznačeno time, da domena vezivanja CD3 sadrži VH sekvencu od SEQ ID NO: 59.
18. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 15 do 17, naznačeno time, da domena vezivanja CD3 sadrži VL sekvencu od SEQ ID NO: 60.
19. Anti-CD79b protutijelo bilo kojeg od patentnog zahtjeva 15, naznačeno time, da domena vezivanja CD3 sadrži sljedećih šest HVR-regija: (a) HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 39; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 40; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 41; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 42; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 43; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 44.
20. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili 19, naznačeno time, da domena vezivanja CD3 sadrži VH sekvencu od SEQ ID NO: 57.
21. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili od 19 do 20, naznačeno time, da domena vezivanja CD3 sadrži VL sekvencu od SEQ ID NO: 58.
22. Anti-CD79b protutijelo patentnog zahtjeva 15, naznačeno time, da domena vezivanja CD3 sadrži sljedećih šest HVR-regija: (a) HVR-H1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 51; (b) HVR-H2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 52; (c) HVR-H3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 53; (d) HVR-L1 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 54; (e) HVR-L2 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 55; i (f) HVR-L3 koja sadrži aminokiselinsku sekvencu od SEQ ID NO: 56.
23. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili 22, naznačeno time, da domena vezivanja CD3 sadrži VH sekvencu od SEQ ID NO: 61.
24. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva 15 ili od 22 do 23, naznačeno time, da domena vezivanja CD3 sadrži VL sekvencu od SEQ ID NO: 62.
25. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 15 do 24, naznačeno time, da (a) domena vezivanja CD3 sadrži Fc domenu, pri čemu Fc domena sadrži zamjenske mutacije T366S, L368A, Y407V i N297G prema EU numeriranju i (b) domena vezivanja CD79b sadrži Fc domenu, pri čemu Fc domena sadrži zamjenske mutacije T366W i N297G prema EU numeriranju.
26. Izolirana nukleinska kiselina, naznačena time, da kodira anti-CD79b protutijelo prema bilo kojem od patentnih zahtjeva od 1 do 25.
27. Vektor, naznačen time, da sadrži izoliranu nukleinsku kiselinu iz zahtjeva 26.
28. Stanica domaćina, naznačena time, da sadrži vektor prema patentnom zahtjevu 27.
29. Imunokonjugat, naznačen time, da sadrži anti-CD79b protutijelo prema bilo kojem od patentnih zahtjeva od 1 do 25 i citotoksično sredstvo.
30. Farmaceutski pripravak, naznačen time, da sadrži anti-CD79b protutijelo prema bilo kojem od patentnih zahtjeva 1 do 25.
31. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 25, naznačeno time, da služi za uporabu u liječenju ili odgođenoj progresiji proliferativnog poremećaja B stanica ili autoimunog poremećaja u ispitanika kojemu je to potrebno.
32. Anti-CD79b protutijelo za uporabu prema patentnom zahtjevu 31, naznačeno time, da je proliferativni poremećaj B stanica limfom, ne-Hodgkinov limfom (NHL), agresivni NHL, relapsni agresivni NHL, relapsni indolentni NHL, refraktorni NHL, refraktori indolentni NHL, kronična limfocitna leukemija (KLL), limfom malih limfocita (LML), leukemija, leukemija vlasastih stanica (LVS), akutna limfocitna leukemija (ALL) i/ili limfom plaštenih stanica.
33. Anti-CD79b protutijelo bilo kojeg od patentnih zahtjeva od 1 do 25 za uporabu u liječenju ili odgođenoj progresiji proliferativnog poremećaja B stanica ili autoimunog poremećaja, naznačeno time, da nadalje sadrži primjenu antagonista proteina PD-1 koji se vezuje za os ili dodatno terapeutsko sredstvo i/ili glukokortikoid i/ili rituksimab kod bolesnika.
HRP20191584 2014-12-05 2015-12-04 Anti-cd79b protutijela i načini uporabe HRP20191584T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088487P 2014-12-05 2014-12-05
PCT/US2015/063902 WO2016090210A1 (en) 2014-12-05 2015-12-04 ANTI-CD79b ANTIBODIES AND METHODS OF USE
EP15816323.8A EP3227336B1 (en) 2014-12-05 2015-12-04 Anti-cd79b antibodies and methods of use

Publications (1)

Publication Number Publication Date
HRP20191584T1 true HRP20191584T1 (hr) 2019-11-29

Family

ID=55022708

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191584 HRP20191584T1 (hr) 2014-12-05 2015-12-04 Anti-cd79b protutijela i načini uporabe

Country Status (33)

Country Link
US (2) US9975949B2 (hr)
EP (1) EP3227336B1 (hr)
JP (2) JP6802158B2 (hr)
KR (1) KR20170086549A (hr)
CN (1) CN107108739B (hr)
AR (1) AR102918A1 (hr)
AU (2) AU2015358325A1 (hr)
BR (1) BR112017011326A2 (hr)
CA (1) CA2966362A1 (hr)
CL (1) CL2017001408A1 (hr)
CO (1) CO2017006740A2 (hr)
CR (1) CR20170230A (hr)
DK (1) DK3227336T3 (hr)
EA (1) EA201790984A1 (hr)
ES (1) ES2744540T3 (hr)
HR (1) HRP20191584T1 (hr)
HU (1) HUE045216T2 (hr)
IL (1) IL251970B (hr)
LT (1) LT3227336T (hr)
MA (1) MA40938A (hr)
MX (1) MX386587B (hr)
MY (1) MY188799A (hr)
PE (1) PE20170953A1 (hr)
PH (1) PH12017500877B1 (hr)
PL (1) PL3227336T3 (hr)
PT (1) PT3227336T (hr)
RS (1) RS59203B1 (hr)
SG (1) SG11201704449VA (hr)
SI (1) SI3227336T1 (hr)
TW (1) TWI713480B (hr)
UA (1) UA120102C2 (hr)
WO (1) WO2016090210A1 (hr)
ZA (1) ZA201703167B (hr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
BRPI0813514A2 (pt) 2007-07-16 2019-09-24 Genentech Inc anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
EP2657253B1 (en) 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2016090210A1 (en) * 2014-12-05 2016-06-09 Genentech, Inc. ANTI-CD79b ANTIBODIES AND METHODS OF USE
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US11078276B2 (en) 2018-10-03 2021-08-03 Nepenthe Bioscience LLC Anti-CD79 antibodies and their uses
US20210317209A1 (en) * 2018-10-30 2021-10-14 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
CN111116745B (zh) * 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用
TW202031686A (zh) * 2019-01-28 2020-09-01 大陸商上海拓界生物醫藥科技有限公司 抗ｃｄ７９ｂ抗體、其抗原結合片段及其醫藥用途
WO2020232169A1 (en) * 2019-05-14 2020-11-19 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
JP2023511163A (ja) * 2020-01-22 2023-03-16 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
BR112023001359A2 (pt) * 2020-07-27 2023-02-14 Tuojie Biotech Shanghai Co Ltd Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
TW202302648A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 Cd79b抗體於自體免疫治療應用之用途
BR112023019484A2 (pt) * 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
EP4330282A1 (en) * 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
CA3231174A1 (en) * 2021-08-02 2023-02-09 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd79bxcd3 bispecific antibody and use thereof
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
CN114891123B (zh) * 2022-06-09 2024-02-09 北京美康基免生物科技有限公司 一种基于CD79b人源化抗体的嵌合抗原受体及其应用
KR20250049549A (ko) * 2022-08-08 2025-04-11 에이티비 테라퓨틱스 CD79b에 대한 인간화된 항체
WO2024081806A2 (en) * 2022-10-12 2024-04-18 Health Research, Inc. Heterogeneity of human cd79 and synergistic enhancement of antitumor activity by co-targeting of cd79b and cd79a in the therapy of b cell tumors
TW202432604A (zh) * 2022-12-29 2024-08-16 大陸商深圳澤安生物醫藥有限公司 抗CD79b抗體及其用途
WO2024145219A2 (en) * 2022-12-29 2024-07-04 Ltz Therapeutics Inc. Anti-cd79b antibodies and uses thereof

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
NZ234586A (en) 1989-07-19 1993-02-25 Arthur Allen Vandenbark Peptide of a t-cell receptor capable of inducing protection from immune-related disease
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
BRPI0813514A2 (pt) * 2007-07-16 2019-09-24 Genentech Inc anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
NZ583367A (en) * 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2657253B1 (en) * 2008-01-31 2017-07-19 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP2267794A4 (en) * 2008-02-08 2015-10-14 Sanyo Electric Co SOLAR CELL MODULE AND SOLAR CELL
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
BR112013002533A2 (pt) 2010-08-02 2021-09-08 Macrogenics, Inc Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica
RS55995B2 (sr) 2010-11-10 2024-04-30 Amgen Res Munich Gmbh Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
ES2659764T3 (es) 2011-08-23 2018-03-19 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T
PE20150614A1 (es) * 2012-07-09 2015-05-25 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
HK1209042A1 (en) 2012-07-09 2016-03-24 基因泰克公司 Immunoconjugates comprising anti-cd79b antibodies
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
JP6133444B2 (ja) 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
EP2968552B1 (en) 2013-03-14 2020-03-11 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
EP3424952A1 (en) * 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
EP3004164A1 (en) 2013-05-28 2016-04-13 Numab AG Novel antibodies
IL296657A (en) 2013-12-17 2022-11-01 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
EA038958B1 (ru) 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
WO2016090210A1 (en) * 2014-12-05 2016-06-09 Genentech, Inc. ANTI-CD79b ANTIBODIES AND METHODS OF USE
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu

Also Published As

Publication number Publication date
IL251970A0 (en) 2017-06-29
CN107108739A (zh) 2017-08-29
TW201636366A (zh) 2016-10-16
BR112017011326A2 (pt) 2018-07-31
MX386587B (es) 2025-03-19
CN107108739B (zh) 2022-01-04
AU2015358325A1 (en) 2017-05-25
IL251970B (en) 2021-12-01
RS59203B1 (sr) 2019-10-31
PE20170953A1 (es) 2017-07-13
US20160159906A1 (en) 2016-06-09
KR20170086549A (ko) 2017-07-26
EP3227336A1 (en) 2017-10-11
JP2018505849A (ja) 2018-03-01
PH12017500877A1 (en) 2017-11-06
ES2744540T3 (es) 2020-02-25
SG11201704449VA (en) 2017-06-29
WO2016090210A1 (en) 2016-06-09
PT3227336T (pt) 2019-09-09
US20180327492A1 (en) 2018-11-15
HK1243102A1 (zh) 2018-07-06
US10941199B2 (en) 2021-03-09
UA120102C2 (uk) 2019-10-10
JP6802158B2 (ja) 2020-12-16
US9975949B2 (en) 2018-05-22
LT3227336T (lt) 2019-09-25
PH12017500877B1 (en) 2017-11-06
SI3227336T1 (sl) 2019-10-30
AR102918A1 (es) 2017-04-05
MA40938A (fr) 2017-10-11
CO2017006740A2 (es) 2018-01-05
DK3227336T3 (da) 2019-09-16
JP2020168006A (ja) 2020-10-15
CL2017001408A1 (es) 2018-01-05
AU2021232717A1 (en) 2021-10-14
PL3227336T3 (pl) 2019-11-29
ZA201703167B (en) 2021-03-31
CA2966362A1 (en) 2016-06-09
EA201790984A1 (ru) 2018-05-31
HUE045216T2 (hu) 2019-12-30
CR20170230A (es) 2017-11-07
TWI713480B (zh) 2020-12-21
MX2017007049A (es) 2018-05-02
MY188799A (en) 2022-01-04
EP3227336B1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
JP2018522541A5 (hr)
JP2017534646A5 (hr)
HRP20240924T1 (hr) Anti - sirpalpha antitijela
HRP20231134T1 (hr) Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
JP2018519364A5 (hr)
HRP20221141T1 (hr) Anti-lag3 protutijela
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
JP2019501883A5 (hr)
HRP20240939T1 (hr) Anti-cd3 protutijela i metode uporabe
JP2016538876A5 (hr)
FI3177643T5 (fi) T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
HRP20211357T1 (hr) Bispecifična protutijela specifična za pd-1 i tim3
JP2019201643A5 (hr)
FI3392276T3 (fi) Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö
JP2019528083A5 (hr)
JP2018527887A5 (hr)
JP2016512551A5 (hr)
JP2019502712A5 (hr)
JP2018035138A5 (hr)
RU2016137110A (ru) Антитела к компоненту комплемента с5
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
HRP20211980T1 (hr) Protutijela protiv sortilina i postupci njihove upotrebe